Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to Clinic
Styx Biotechnologies, Inc., a San Diego-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, today announced a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected Styx ADC programs toward first-in-human clinical studies.
